| Old Articles: <Older 4521-4530 Newer> |
|---|
 |
The Motley Fool
January 24, 2008
Brian Orelli |
Abbott Goes Global The drugmaker wraps up a solid 2007 with successful expansion overseas.   |
The Motley Fool
January 24, 2008
Brian Lawler |
Pfiltering Through Pfizer's Year Pfizer releases its 2007 numbers, displaying year-over-year earnings growth powered by foreign currency gains. |
The Motley Fool
January 23, 2008
Brian Orelli |
Teva Buys In to Biologics Teva Pharmaceutical announces that it was acquiring privately held CoGenesys, for $400 million in cash. |
The Motley Fool
January 22, 2008
Brian Orelli |
The Little Anti-Inflammatory That Could Abbott Laboratories gets yet another approval for Humira, this time to treat chronic plaque psoriasis. |
The Motley Fool
January 22, 2008
Brian Lawler |
Seattle Genetics' Fortuitous Timing The drugmaker raises some much-needed cash with a $90 million stock offering. |
The Motley Fool
January 22, 2008
Brian Lawler |
Adolor Under the FDA's Spotlight The FDA releases its documents on Adolor's lead drug, with surprising good news in advance of an advisory panel discussion. Investors, take note. |
Fast Company
February 1, 2008
Amy Feldman |
Artery, Heal Thyself Abbott's new absorbable stent could change heart surgery and revive a $5 billion business. |
Fast Company
February 1, 2008
Arianne Cohen |
Scuttling Scut Work Pfizer devises a new kind of outsourcing -- just for the time-wasting parts of your job. |
The Motley Fool
January 18, 2008
Brian Lawler |
Wrong-Way Regulators in Europe European Union regulators raided operations of multiple large pharmaceutical companies looking for antitrust and anticompetitive actions in both the branded and generic sectors. They're looking in the wrong places. |
The Motley Fool
January 18, 2008
Brian Orelli |
The Battle of the Thrombins ZymoGenetics announces that its recombinant thrombin product, Recothrom, was given a thumbs-up by the FDA. |
| <Older 4521-4530 Newer> Return to current articles. |
